Antimycobacterial Agents: New Advances in Combating Drug-Resistant Tuberculosis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 44
Special Issue Editor
Special Issue Information
Dear Colleagues,
Despite the medical and social interventions observed for over a century, tuberculosis (TB)—caused by mycobacterium tuberculosis (MTB)— remains a formidable global health challenge, accounting for over 1.5 million fatalities annually. The absence of an effective vaccine against tuberculosis necessitated the broad administration of antibiotics over the past few decades, which, almost inevitably, has hastened the rise in and spread of drug-resistant (DR) and multi-drug-resistant (MDR) Mtb strains globally. Are we able to devise innovative antimicrobial measures faster than TB's drug resistance evolves? Can we develop a quick, accurate, and affordable drug sensitivity tests (DSTs) for all? Clearly, addressing these monumental challenges requires combined efforts from the TB research community and beyond.
In light of this, I am thrilled to invite contributions to our Special Issue titled “Antimycobacterial Agents: Combating Drug-Resistant Tuberculosis” in Pharmaceutics. While contributions can be diverse, potential topics might include the following:
- New chemical or biological antimicrobial methods, such as phage- or host-directed therapy.
- Insights into the molecular mechanisms and clinical diagnosis of TB drug resistance.
- Technological breakthroughs in studying the interaction between drugs and bacteria.
I eagerly await the opportunity to collaborate and spotlight your significant scientific discoveries.
Dr. Junhao Zhu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimycobacterial agents
- mycobacterium tuberculosis
- drug-resistant
- tuberculosis
- antimicrobial
